Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years.
- Trial name
- MOVE PAH) (NCT05464095)
- Testing
- mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other…
- Trial name
- NCT05224531
- Testing
- CS1 Administration
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Cereno Scientific AB
Pulmonary Arterial Hypertension
Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development…
- Trial name
- NCT05135000
- Testing
- LTP001
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment.
- Trial name
- VIP (NCT03556020)
- Testing
- Pemziviptadil (PB1046)
- Where
- 26 sites in United States
- Volunteers
- 35 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Subcutaneous Elafin in Healthy Subjects
A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult subjects.
- Trial name
- NCT03522935
- Testing
- Elafin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roham T. Zamanian
Pulmonary Arterial Hypertension
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH).
- Trial name
- PHoenix (NCT05825417)
- Testing
- Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Eisenmenger Complex
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome
In this study, the investigator will evaluate the treatment effects and safety, patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan.
- Trial name
- NCT04732650
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Pulmonary Arterial Hypertension
Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing…
- Trial name
- OrPHeUS (NCT03197688)
- Testing
- Notapplicable
- Where
- 106 sites in United States, Puerto Rico
- Volunteers
- 2,200 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension (PAH), Sleep-disordered Breathing (SDB)
PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease characterized by increased pulmonary vascular resistance, right ventricular dysfunction, and clinically important morbidity and mortality.
- Trial name
- PAH-SDB (NCT07852403)
- Testing
- Standardized Overnight Sleep and Cardiorespiratory Monitoring
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Interstitial Lung Disease, Comorbidities and Coexisting Conditions
Taiwan Interstitial Lung Disease Multi-center Investigation and Registry
The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease.
- Conditions
- Interstitial Lung Disease, Comorbidities and Coexisting Conditions, Pulmonary Arterial Hypertension, Treatment Adherence
- Trial name
- TAILI (NCT06476470)
- Where
- Taiwan
- Volunteers
- 10,000 people
- Sponsor
- Taichung Veterans General Hospital
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated.
- Trial name
- AIPHY (NCT05566002)
- Testing
- Right heart catheterization
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Arterial Hypertension (PAH)
Telerehabilitation in Pulmonary Arterial Hypertension
Context: Pulmonary arterial hypertension (PAH) causes severe exercise intolerance and reduced quality of life, while access to supervised rehabilitation remains limited.
- Trial name
- TRHP-001 (NCT07799675)
- Testing
- Home-based telerehabilitation program
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Pulmonary Artery Hypertension
Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
The aim of the study is that evaluation of basic and accessory respiratory muscles and their relationship of six minute walk test in patient with pulmonary arterial hypertension (PAH)
- Trial name
- NCT05056532
- Testing
- patient assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Giresun University
Hypertension, Pulmonary
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
The purpose of this study is to determine whether the study drug is effective in the long-term treatment of primary or secondary pulmonary hypertension
- Trial name
- NCT00414687
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Volunteers
- 63 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)
Patients with pulmonary arterial hypertension(PAH) suffer from chronic shortness of breath, and have impaired survival related to progressive right ventricular failure.
- Trial name
- MELISSA (NCT01181284)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).
- Trial name
- PATENT-1 (NCT00810693)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 122 sites in United States, Argentina and 28 more
- Volunteers
- 445 people
- Sponsor
- Bayer
Primary and Secondary Pulmonary Hypertension
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension
- Trial name
- NCT00155714
- Testing
- type-5 phosphodiesterase Inhibitor (Sildenafil)
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Hypertension, Diabetes
Retrieval of Economic Incentives and Information on Quality-of-care Indicators in Primary Care
Background: Information provision and economic incentives for professionals are measures aimed at improving quality-of-care in primary care.
- Conditions
- Hypertension, Diabetes, Atrium; Fibrillation, Asthma
- Trial name
- NCT06829589
- Testing
- Removal of economic incentives linked to 7 quality-of-care indicators, Removal of information provision linked to 7 quality-of-care indicators
- Where
- 68 sites in Spain
- Volunteers
- 1,614 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH)…
- Trial name
- NCT00796510
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 3 sites in United States, Romania and 1 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible…
- Trial name
- RELIEVE-PAH (NCT03838445)
- Testing
- V-Wave Interatrial Shunt
- Where
- 3 sites in United States, Mexico
- Volunteers
- 9 people
- Sponsor
- V-Wave Ltd